Philips Healthcare put a new twist on SPECT/CT with the unveiling at the SNM meeting in June of a hybrid that incorporates a flat-panel x-ray system in place of the typical multislice CT. The novel combination is attuned specifically to the needs of specialists in nuclear medicine, said Jay Mazelsky, senior vice president and general manager of Philips nuclear medicine.
Philips Healthcare put a new twist on SPECT/CT with the unveiling at the SNM meeting in June of a hybrid that incorporates a flat-panel x-ray system in place of the typical multislice CT. The novel combination is attuned specifically to the needs of specialists in nuclear medicine, said Jay Mazelsky, senior vice president and general manager of Philips nuclear medicine.
"BrightView XCT provides the localization and attenuation correction, fits the budget, has relatively low complexity, and doesn't require special training for technologists," Mazelsky said. "These things are important for the nuclear medicine user."
The XCT design is compact enough to allow siting in the same 12 × 15-foot room as the SPECT camera alone. As with other hybrids, SPECT and CT scans done during the same examination eliminate the need to reregister the data.
When it begins shipping next year, the BrightView XCT, slated to begin beta testing in Q1 2009, will occupy an appealing financial niche in the Philips portfolio of SPECT/CT hybrids. Its price will fall somewhere between the $700,000 six-slice Precedence SPECT/CT and the $350,000 BrightView gamma camera, which captures the SPECT data as
part of the BrightView XCT.
The x-ray system built into the new hybrid is what provides the cost flexibility, as its flat-panel detector costs substantially less than conventional CT detectors.
The BrightView XCT detector still captures data that can be turned into volumetric reconstructions, however, while delivering high-resolution images up to 15 line pairs/cm, according to Mazelsky. A side benefit is a two-thirds reduction in patient x-ray dose compared with multislice CT.
Volumetric data reconstructions are performed using software developed for the XCT. This software, also introduced at the SNM meeting, is made up of a nuclear medicine application portfolio that runs on Philips' Extended Brilliance Workspace (EBW), a workstation developed specifically to be used with the company's imaging modalities.
Philips currently runs its JetStream software on the EBW workstation. Nuclear medicine departments will be able to buy versions of the more advanced application portfolio early next year for use in both scanners. The scalable software will allow buyers the option to upgrade from SPECT to SPECT/CT, if and when the need arises, Mazelsky said.
-By Greg Freiherr
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.